scispace - formally typeset
M

Ming Chen

Researcher at Shanghai Jiao Tong University

Publications -  7
Citations -  70

Ming Chen is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 2, co-authored 2 publications receiving 43 citations.

Papers
More filters
Journal ArticleDOI

Expression of GPC3 protein and its significance in lung squamous cell carcinoma

TL;DR: The expression of GPC3 protein in lung squamous cell carcinoma was significantly higher than that in adjacent normal tissues, and G PC3 protein expression increased with lowering degrees of tumor differentiation, and the association of initiation, development, invasion, and metastasis of disease is warranted.
Journal ArticleDOI

A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma

TL;DR: The risk score model could independently predict OS in patients with LUAD, and highly correlated with stemness scores and numerous m6A, m5C, m1A and m7G modification-related genes, and was significantly correlated with multiple immune microenvironment characteristics.
Journal ArticleDOI

Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer.

TL;DR: Gender, vascular endothelial growth factor-A and E-cadherin expression were significant predictive factors for overall survival in completely resected pathologic stage I non-small cell lung cancer.
Journal ArticleDOI

Potential Values of Circulating microRNA-21 to Predict Early Recurrence in Patients with Colorectal Cancer after Treatments

TL;DR: Improved prognosing efficacy in CRC recurrence and better outcomes to significantly differentiate recurrence in stratified patients could be obtained by analysing combined biomarkers.
Journal ArticleDOI

Development of a novel glycolysis-related genes signature for isocitrate dehydrogenase 1-associated glioblastoma multiforme

TL;DR: Construction of GRGs prognostic signature and identification of close correlation between the signature and immune landscape would suggest its potential applicability in immunotherapy of GBM in the future.